Biochem/physiol Actions

Primary TargetCa2+-activated K+ channels

General description

A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC₅₀ = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.

A potent activator of Ca2+ -activated K+ channels of SK and IK types but not BK type channels. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell. NS309 blocks L-type Calcium channels with IC₅₀ = 10 µM/L. Recently, this compound has been shown to produce endothelium-dependent hyperpolarizations in guinea pig carodid arteries by opening KCa2.3 and KCa3.1 channels demonstrating a new therapeutic option for treating hypertension.Please note that the molecular weight for this compound is batch-specific due to variable water content.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Leurangue, V. et al. 2008. Naunyn Schmiedebergs Arch. Pharmacol.377, 101.Morimura, K. et al. 2006. J. Pharmacol. Sci.100, 237.Strobaek, D. et al. 2004. Biochim. Biophys. Acta.1665, 1.

Packaging

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)